| 1. | World Health Organization (WHO). Global battle against cancer won’t be won with treatment alone-effective prevention measures urgently needed to prevent cancer crisis. Cent Eur J Public Health, 2014, 22(1): 23, 28. | 
				                                                        
				                                                            
				                                                                | 2. | McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis, 2011, 15(2): 223-243. | 
				                                                        
				                                                            
				                                                                | 3. | Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol, 2008, 48 Suppl 1: S20-S37. | 
				                                                        
				                                                            
				                                                                | 4. | Yuen MF, Cheng CC, Lauder IJ, et al. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology, 2000, 31(2): 330-335. | 
				                                                        
				                                                            
				                                                                | 5. | Chalasani N, Said A, Ness R, et al. Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: results of a national survey. Am J Gastroenterol, 1999, 94(8): 2224-2229. | 
				                                                        
				                                                            
				                                                                | 6. | Vogl TJ, Kümmel S, Hammerstingl R, et al. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology, 1996, 200(1): 59-67. | 
				                                                        
				                                                            
				                                                                | 7. | Choi JW, Lee JM, Kim SJ, et al. Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR images and their value as an imaging biomarker. Radiology, 2013, 267(3): 776-786. | 
				                                                        
				                                                            
				                                                                | 8. | Kitao A, Matsui O, Yoneda N, et al. Hypervascular hepatocellular carcinoma: correlation between biologic features and signal intensity on gadoxetic acid-enhanced MR images. Radiology, 2012, 265(3): 780-789. | 
				                                                        
				                                                            
				                                                                | 9. | Yamashita T, Kitao A, Matsui O, et al. Gd-EOB-DTPA-enhanced magnetic resonance imaging and alpha-fetoprotein predict prognosis of early-stage hepatocellular carcinoma. Hepatology, 2014, 60(5): 1674-1685. | 
				                                                        
				                                                            
				                                                                | 10. | Shin SK, Kim YS, Shim YS, et al. Peritumoral decreased uptake area of gadoxetic acid enhanced magnetic resonance imaging and tumor recurrence after surgical resection in hepatocellular carcinoma: A STROBE-compliant article. Medicine (Baltimore), 2017, 96(33): e7761. | 
				                                                        
				                                                            
				                                                                | 11. | Asayama Y, Tajima T, Nishie A, et al. Uptake of Gd-EOB-DTPA by hepatocellular carcinoma: radiologic-pathologic correlation with special reference to bile production. Eur J Radiol, 2011, 80(3): e243-e248. | 
				                                                        
				                                                            
				                                                                | 12. | Korean Society of Abdominal Radiology. Diagnosis of hepatocellular carcinoma with gadoxetic acid-enhanced MRI: 2016 Consensus Recommendations of the Korean Society of Abdominal Radiology. Korean J Radiol, 2017, 18(3): 427-443. | 
				                                                        
				                                                            
				                                                                | 13. | Kim SH, Kim SH, Lee J, et al. Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol, 2009, 192(6): 1675-1681. | 
				                                                        
				                                                            
				                                                                | 14. | Hwang J, Kim SH, Lee MW, et al. Small (≤2 cm) hepatocellular carcinoma in patients with chronic liver disease: comparison of gadoxetic acid-enhanced 3.0 T MRI and multiphasic 64-multirow detector CT. Br J Radiol, 2012, 85(1015): e314-e322. | 
				                                                        
				                                                            
				                                                                | 15. | Kim HD, Lim YS, Han S, et al. Evaluation of early-stage hepatocellular carcinoma by magnetic resonance imaging with gadoxetic acid detects additional lesions and increases overall survival. Gastroenterology, 2015, 148(7): 1371-1382. | 
				                                                        
				                                                            
				                                                                | 16. | Yoo SH, Choi JY, Jang JW, et al. Gd-EOB-DTPA-enhanced MRI is better than MDCT in decision making of curative treatment for hepatocellular carcinoma. Ann Surg Oncol, 2013, 20(9): 2893-2900. | 
				                                                        
				                                                            
				                                                                | 17. | Choi JY, Kim MJ, Park YN, et al. Gadoxetate disodium-enhanced hepatobiliary phase MRI of hepatocellular carcinoma: correlation with histological characteristics. AJR Am J Roentgenol, 2011, 197(2): 399-405. | 
				                                                        
				                                                            
				                                                                | 18. | Fujita N, Nishie A, Kubo Y, et al. Hepatocellular carcinoma: clinical significance of signal heterogeneity in the hepatobiliary phase of gadoxetic acid-enhanced MR imaging. Eur Radiol, 2015, 25(1): 211-220. | 
				                                                        
				                                                            
				                                                                | 19. | Kiryu S, Akai H, Nojima M, et al. Impact of hepatocellular carcinoma heterogeneity on computed tomography as a prognostic indicator. Sci Rep, 2017, 7(1): 12689. | 
				                                                        
				                                                            
				                                                                | 20. | de Lope CR, Tremosini S, Forner A, et al. Management of HCC. J Hepatol, 2012, 56 Suppl 1: S75-S87. | 
				                                                        
				                                                            
				                                                                | 21. | Ruà S, Comino A, Fruttero A, et al. Flow cytometric DNA analysis of cirrhotic liver cells in patients with hepatocellular carcinoma can provide a new prognostic factor. Cancer, 1996, 78(6): 1195-1202. | 
				                                                        
				                                                            
				                                                                | 22. | Duseja A. Staging of hepatocellular carcinoma. J Clin Exp Hepatol, 2014, 4(Suppl 3): S74-S79. | 
				                                                        
				                                                            
				                                                                | 23. | Huppertz A, Haraida S, Kraus A, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT—initial observations. Radiology, 2005, 234(2): 468-478. | 
				                                                        
				                                                            
				                                                                | 24. | 劉曦嬌, 唐鶴菡, 張笑, 等. 釓塞酸二鈉增強 MRI 肝膽期信號與肝細胞肝癌分化程度的關系. 中國普外基礎與臨床雜志, 2014, 21(12): 1583-1586. | 
				                                                        
				                                                            
				                                                                | 25. | Nanashima A, Abo T, Tobinaga S, et al. Relationship between period of survival and clinicopathological characteristics in patients with hepatocellular carcinoma who underwent hepatectomy. Hepatogastroenterology, 2010, 57(99-100): 540-546. | 
				                                                        
				                                                            
				                                                                | 26. | Miyaaki H, Nakashima O, Kurogi M, et al. Lens culinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma. J Gastroenterol, 2007, 42(12): 962-968. |